

Biogel Eclipse® range

Chemotherapy agent permeation



Tested for use with
chemotherapy agents

Agent tested	CAS no. (active ingredient)	Concentration	Biogel Eclipse REF 750 / REF 751 / REF 752	Biogel Eclipse Indicator Underglove REF 732 / REF 609	Biogel Eclipse Indicator System REF 607 / REF 608
Bleomycin (Blenoxane)	9041-93-4	15 mg/ml	>240	>240	not tested
Busulfan	55-98-1	6 mg/ml	>240	>240	not tested
Carboplatin (Paraplatin)	41575-94-4	10 mg/ml	>240	>240	not tested
Carmustine* (BCNU)	154-93-8	3.3 mg/ml	12.1	11.7	36.8
Cisplatin	15663-27-1	1 mg/ml	>240	>240	not tested
Cyclophosphamide (Cytoxan)	50-18-0	20 mg/ml	>240	>240	not tested
Cytarabine	147-94-4	100 mg/ml	>240	>240	not tested
Dacarbazine (DTIC)	4342-03-4	10 mg/ml	>240	>240	not tested
Doxorubicin Hydrochloride	23214-92-8	2 mg/ml	>240	>240	not tested
Ellence	56420-45-2	2 mg/ml	>240	>240	not tested
Etoposide (Toposar)	33419-42-0	20 mg/ml	>240	>240	not tested
Fludarabine	21679-14-1	25 mg/ml	>240	>240	not tested
Fluorouracil	51-21-8	50 mg/ml	>240	>240	not tested
Idarubicin	57852-57-0	1 mg/ml	>240	>240	not tested
Ifosfamide	3778-73-2	50 mg/ml	>240	>240	not tested
Irinotecan	100286-90-6	20 mg/ml	>240	not tested	>240
Mechlorethamine HCl	55-86-7	1 mg/ml	>240	>240	not tested
Melphalan	148-82-3	5 mg/ml	>240	>240	not tested
Methotrexate	59-05-2	25 mg/ml	>240	>240	not tested
Mitomycin C	50-07-7	0.5 mg/ml	>240	>240	not tested
Mitoxantrone	70476-82-3	2 mg/ml	>240	>240	not tested
Oxaliplatin	63121-00-6	2 mg/ml	>240	not tested	not tested
Paclitaxel (Taxol)	33069-62-4	6 mg/ml	>240	>240	not tested
Rituximab	174722-31-7	10 mg/ml	>240	>240	not tested
Thiotepa*	52-24-4	10 mg/ml	14.1	15.6	57.2
Vincristine Sulfate	57-22-7	1 mg/ml	>240	>240	not tested

Test Results Based on ASTM D6978-05 Test Method Breakthrough detection time in minutes (0.01 µg/cm²/minutes)

Note: The Biogel Eclipse®, Biogel Eclipse® Indicator® Underglove and Biogel Eclipse® Indicator® System surgical gloves are intended to be worn on the hands, usually in the surgical settings, to provide barrier against potentially infectious material and other contaminants.

In addition, these gloves were tested at an independent test facility for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs.

Breakthrough detection times may not reflect the actual duration of protection in the workplace due to other factors influencing the performance, such as temperature, abrasion, puncture, degradation etc.

Gloves used for protection against chemotherapy drug exposure should be selected specifically for the types of chemical used. Users should review this information with information provided with the drug e.g. drug labeling or material safety data sheets for the chemicals being used to determine an adequate level of protection for the intended use.

***Warning:** Do not use single gloves for protection against Carmustine (3.3 mg/ml) and Thiotepa (10 mg/ml). Consider using additional safety controls when handling these materials to avoid contact as well as the use of multiple gloves with longer breakthrough detection times.

Performance level, breakthrough detection time

>240	121-240	61-120	31-60	11-30	≤10	not tested
------	---------	--------	-------	-------	-----	------------

All times are in minutes

Find out more at molnlycke.com

Mölnlycke Health Care AB, P.O. Box 13080, Gamlestadsvägen 3 C, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00. The Mölnlycke, Biogel, Eclipse and Indicator trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care group of companies.
©2024 Mölnlycke Health Care AB. All rights reserved. HQIM005986

